Press release: dupixent approved in china as the first-ever biologic medicine for patients with copd

Dupixent approved in china as the first-ever biologic medicine for patients with copd approval follows eu approval of dupixent for adults with copd with raised blood eosinophils, and is based on two landmark phase 3 studies showing dupixent significantly reduced exacerbations, improved lung function, and also improved health-related quality of life copd is the most prevalent chronic respiratory disease in china, and is a priority within the government's healthy china 2030 public health plan dupixent is now approved in four indications across respiratory and dermatological diseases in china paris and tarrytown, new york, sept. 27, 2024. the national medical products administration (nmpa) in china has approved dupixent (dupilumab) as an add-on maintenance treatment for adults with uncontrolled chronic obstructive pulmonary disease (copd) characterized by raised blood eosinophils.
REGN Ratings Summary
REGN Quant Ranking